Qualigen Therapeutics, INC. (AIXC) SEC Filings — 2024
32 SEC filings for Qualigen Therapeutics, INC. (AIXC) in 2024.
Filings
- Qualigen Therapeutics Files 8-K: Security Holder Rights Modified — 8-K · Dec 26, 2024
- Qualigen Therapeutics Files S-1 for Securities Offering — S-1 · Dec 9, 2024
- Qualigen Therapeutics Files 8-K/A Amendment — 8-K/A · Nov 21, 2024
- Qualigen Therapeutics Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024
- Qualigen Therapeutics Announces Board and Executive Changes — 8-K · Nov 13, 2024
- Qualigen Therapeutics Files 8-K on Security Holder Rights — 8-K · Nov 8, 2024
- Qualigen Therapeutics Relocates Principal Executive Offices — 8-K · Nov 1, 2024
- Qualigen Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Oct 29, 2024
- Qualigen Therapeutics Files S-1 Registration — S-1 · Oct 24, 2024
- Qualigen Therapeutics Faces Nasdaq Delisting Warning — 8-K · Oct 22, 2024
- Qualigen Therapeutics Appoints New Chief Medical Officer — 8-K · Oct 9, 2024
- Qualigen Therapeutics Board Changes Announced — 8-K · Sep 26, 2024
- Qualigen Therapeutics Files 8-K — 8-K · Sep 20, 2024
- Qualigen Therapeutics Files Definitive Proxy Statement — DEF 14A · Sep 10, 2024
- Qualigen Therapeutics Enters Material Definitive Agreement — 8-K · Sep 9, 2024
- Qualigen Therapeutics Files 8-K — 8-K · Sep 5, 2024
- Qualigen Therapeutics Files S-1/A Amendment — S-1/A · Aug 22, 2024
- Qualigen Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 14, 2024
- Qualigen Therapeutics Files S-1/A Amendment — S-1/A · Aug 9, 2024
- Qualigen Therapeutics Files S-1/A Amendment — S-1/A · Aug 7, 2024
- Qualigen Therapeutics Faces Nasdaq Delisting Warning — 8-K · Aug 5, 2024
- Qualigen Therapeutics Files 8-K: Material Definitive Agreement — 8-K · Jul 18, 2024
- Qualigen Therapeutics Secures $10M Loan from Innoviva — 8-K · Jul 15, 2024
- Qualigen Therapeutics Announces Change of Control and Executive Changes — 8-K · Jul 11, 2024
- Qualigen Therapeutics Files Q1 2024 10-Q — 10-Q · Jul 2, 2024
- Qualigen Therapeutics Faces Delisting Concerns — 8-K · May 30, 2024
- Qualigen Therapeutics, Inc. Files Amendment to S-1 Registration Statement — S-1/A · May 6, 2024
- Qualigen Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · Apr 16, 2024
- Qualigen Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 8, 2024
- Qualigen Therapeutics Terminates Material Definitive Agreement — 8-K · Mar 28, 2024
- Qualigen Reports Multiple Corporate Actions: Agreements, Debt, Equity Sales, and Officer Changes — 8-K · Feb 27, 2024
- Qualigen Therapeutics Enters Material Definitive Agreement — 8-K · Feb 22, 2024